A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Guangdong Association of Clinical Trials
Henan Cancer Hospital
Betta Pharmaceuticals Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Nanfang Hospital, Southern Medical University
Betta Pharmaceuticals Co., Ltd.
The First Affiliated Hospital of Soochow University
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Sun Yat-sen University
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
China Medical University, China
ChineseAMS
ChineseAMS
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Henan Provincial People's Hospital
Hangzhou Cancer Hospital
Qilu Hospital of Shandong University
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Nanfang Hospital, Southern Medical University
People's Hospital of Guangxi Zhuang Autonomous Region
Zhejiang University
Betta Pharmaceuticals Co., Ltd.
Nanfang Hospital, Southern Medical University
Shandong Cancer Hospital and Institute
Zhejiang Cancer Hospital